FDA
-
-
-
-
-
-
-
Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
-
-
-
-
-
-
-
Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update
-
-
-
-
-
-
-
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
-
-
-
-
-
-
-
Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness
-
-
-
-
-
-
-
Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update
-
-
-
-
-
-
-
Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
-
-
-
-
-
-
-
Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million
-
323,398 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

